Alcon ALC.SW
What does Alcon do?
Alcon is a medical technology company specializing in eye care, based in Switzerland. It develops, manufactures and sells products for eye surgery as well as for vision correction and eye health. The business is divided into two segments: Surgical and Vision Care.
In the Surgical segment, Alcon earns money with devices, diagnostics and visualization systems for cataract and retinal surgery, with intraocular lenses and other implants, and with consumables that are needed on a recurring basis. Customers are mainly clinics and eye surgeons. Vision Care comprises contact lenses and eye care products such as lubricating drops, which are sold through opticians, distributors and retail. Alcon is among the world's largest eye care providers, with a strong market position in cataract surgery. Competitors include Johnson & Johnson Vision, Bausch + Lomb, Zeiss and CooperVision.
Score profile
Rank vs. Medical Instruments & Supplies (28 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.
Metrics compared with the industry
On profitability and quality, Alcon ranks in the middle in the group Medical Instruments & Supplies (4.7/10). On growth, the company ranks above average in the group Medical Instruments & Supplies (6.2/10). On valuation (higher = cheaper), the stock ranks in the middle in the group Medical Instruments & Supplies (5.0/10). On financial strength, Alcon ranks above average in the group Medical Instruments & Supplies (6.0/10).
| Metric | Stock | Group median | Ranking |
|---|---|---|---|
| Forward P/E | 17.0x | 18.5x | better than 63 % |
| Trailing P/E | 56.3x | 34.2x | better than 20 % |
| PEG ratio | 1.3x | 1.3x | better than 52 % |
| EV/EBITDA | 16.2x | 15.7x | better than 43 % |
| Price/sales | 3.2x | 3.1x | better than 41 % |
| Price/book | 1.7x | 2.8x | better than 83 % |
| Revenue growth | 4.7% | 4.7% | better than 50 % |
| Earnings growth | 12.5% | 0.0% | better than 73 % |
| Gross margin | 57.9% | 54.7% | better than 55 % |
| Operating margin | 12.9% | 12.9% | better than 54 % |
| Net margin | 6.1% | 8.5% | better than 41 % |
| Return on equity | 3.0% | 6.3% | better than 38 % |
| Debt/equity | 24.6% | 36.0% | better than 63 % |
| Current ratio | 2.5x | 2.3x | better than 65 % |
| Free cash flow yield | 3.6% | 3.4% | better than 52 % |
| Dividend yield | 0.5% | 0.9% | – |
| Payout ratio | 25.6% | 38.9% | – |
| Beta | 0.72 | 0.85 | – |
Valuation: what is Alcon worth?
Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Alcon a model range of 43.62 CHF to 70.25 CHF per share.
17 analysts, average rating “Buy”, average price target 73.96 CHF (+20.5%).
The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.
What the business depends on
- Demand for cataract surgery is rising structurally with population aging and growing access to eye care.
- Installed devices generate recurring revenue from consumables and implants, which stabilizes sales.
- Innovations in premium lenses and contact lenses allow for higher prices and strengthen the market position against competitors.
Risks
- Competitors with comparable products and price pressure can weigh on market share and margins in the lens and contact lens business.
- Regulatory requirements and approval procedures for medical devices can delay market launches and increase costs.
- Exchange rate fluctuations and weaker consumer sentiment for self-paid premium procedures can affect revenue and earnings.
What to look for with Alcon
The operating margin is informative, as it shows how well Alcon translates pricing power, product mix and research and sales costs into profitable growth.